In a not-so-shocking turn of events, Pfizer Inc. is now under intense scrutiny as investigators demand documents related to their COVID-19 vaccine. The investigation seeks information on several aspects of the vaccine’s development and marketing, including communications with regulatory bodies, safety and efficacy concerns, and potential whistleblower reports.
#Pfizer #Investigation #AntitrustViolations
Texas A.G. Consumer Protection Division issues CIVIL INVESTIGATIVE DEMAND to Pfizer Inc.
Pfizer must supply ALL documents – NO REDACTION – by 31st May 2023
‘Discovery’ could reach back as far as 1990
more: https://t.co/Dyy7zGSJeF pic.twitter.com/NtjhPux4NP
— 🥸 mR NArrative – at your service(?) (@nada88564211) May 10, 2023
One of the primary focuses of the investigation is any correspondence Pfizer may have had with the FDA, CDC, WHO, and other regulatory organizations. Additionally, the investigation aims to uncover any internal discussions within Pfizer’s risk management committees that might shed light on the safety and effectiveness of the company’s COVID-19 vaccine and their mRNA technology.
Pfizer is also facing inquiries regarding whistleblower reports or concerns related to their COVID-19 vaccine trials, the safety and efficacy of the vaccine, as well as the transmissibility of COVID-19 after vaccination. Another controversial topic under investigation is Pfizer’s potential involvement in a gain of function or directed evolution research in developing the COVID-19 vaccine. The outcome of this investigation could have significant implications for Pfizer and the broader pharmaceutical industry. These investigations have sparked debates over pharmaceutical transparency and ethical research practices, intensifying scrutiny on Pfizer’s operations. Additionally, the company faces pressure to address unrelated industry challenges, such as cybersecurity concerns, with some experts drawing parallels to the urgency surrounding the Nvidia security flaw deadline. The convergence of these issues underscores the mounting complexities pharmaceutical giants must navigate in a rapidly evolving global landscape.
Full Document:
.
Carl Riedel is an experienced writer focused on using Open Source Intelligence (OSINT) to produce insightful articles. Passionate about free speech, he leverages OSINT to delve into public data, crafting stories that illuminate underreported issues, enriching public discourse with perspectives often overlooked by mainstream media.
